How many drugs treat Allergic Reactions?

Drug Landscape tracks 2 marketed treatments for Allergic Reactions (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Allergic Reactions?

Most recent: Bupivacaine Hydrochloride And Epinephrine — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/allergic-reactions.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Allergic Reactions — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allergic Reactions (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Allergic Reactions, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Epipen	epinephrine	Pfizer Inc.	alpha-Adrenergic Agonist [EPC]	Alpha-1D adrenergic receptor		1948-01-01
Epinephrin	Epinephrin	United States Naval Medical Center, San Diego		Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-30 — Bupivacaine Hydrochloride And Epinephrine · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer Inc. · 2 drugs in Allergic Reactions
United States Naval Medical Center, San Diego · 1 drug in Allergic Reactions

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Allergic Reactions:

Cite this brief

Drug Landscape (2026). Allergic Reactions — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/allergic-reactions. Accessed 2026-06-10.

Allergic Reactions full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing